You are here

Cancer Informatics

Cancer Informatics

J.T. Efird University of Newcastle, Australia
Managing Editor
Barbara Rattner, PhD SAGE Publishing, Thousand Oaks, CA USA

eISSN: 11769351 | ISSN: 11769351 | Current volume: 17 | Current issue: 1

Journal Highlights

  • Indexed using PubMed Central (PMC), ESCI, Scopus, and DOAJ
  • Published since 2008
  • Publication is subject to payment of an article processing charge (APC)

Cancer Informatics is an open access, peer reviewed, international journal that focuses on reporting bioinformatics analyses of molecular genetics and/or clinical data pertaining to human cancer risk, prevention, outcome, or treatment response. Please see the Aims and Scope tab for further information.

This journal is a member of the Committee on Publication Ethics (COPE).

Submission Information

Submit your manuscript here.
Please see the Submission Guidelines tab for more information on how to submit your article to the journal.

Open access article processing charge (APC) information

Publication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons license.

The APC for this journal is currently $1848 USD.

The article processing charge (APC) is payable only if your article is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.


Please direct any queries to

The field of cancer research relies on advances in many other disciplines, including omics technology, mass spectrometry, radio imaging, computer science, and biostatistics. Cancer Informatics provides open access to peer-reviewed high-quality manuscripts reporting bioinformatics analysis of molecular genetics and/or clinical data pertaining to cancer, emphasizing the use of machine learning, artificial intelligence, statistical algorithms, advanced imaging techniques, data visualization, and high-throughput technologies. As the leading journal dedicated exclusively to the report of the use of computational methods in cancer research and practice, Cancer Informatics leverages methodological improvements in systems biology, genomics, proteomics, metabolomics, and molecular biochemistry into the fields of cancer detection, treatment, classification, risk-prediction, prevention, outcome, and modeling.

Manuscript Submission

  • Submit your manuscript here.
  • Please refer to the Submission Guidelines tab for more information before submitting your manuscript.

Editor in Chief
J.T. Efird University of Newcastle, Australia
Deputy Editor
Zemin Zhang Peking University, China
Editorial Board
Hoda Anton-Culver University of California, Irvine, USA
Michael J. Becich University of Pittsburgh, USA
Idriss M. Bennani-Baiti Cancer Epigenetics Society, Austria
Silvio Bicciato University of Modena and Reggio Emilia, Italy
Serdar Bozdag Marquette University, USA
Benedikt Brors German Cancer Research Center, Germany
Enrico Capobianco National Research Council of Italy, Italy
Arul Chinnaiyan University of Michigan, USA
Robert Clarke Georgetown University Medical Center, Washington, D.C., USA
Robert C. Cockrell University of Vermont, USA
Kevin Coombes University of Texas, USA
Rebecca Crowley University of Pittsburgh School of Medicine, USA
Roger Day University of Pittsburgh, USA
Thomas S. Deisboeck Massachusetts General Hospital, USA
Eytan Domany Weizmann Institute of Science, Israel
Edward R. Dougherty Texas A&M University, USA
Ziding Feng Fred Hutchinson Cancer Research Center, USA
David J. Foran Rutgers Cancer Institute of New Jersey, USA
Ge Gao Peking University, China
Jianjiong Gao Memorial Sloan Kettering Cancer Center, USA
Debashis Ghosh Penn State University, USA
Judith D. Goldberg New York University School of Medicine, USA
Alex Graudenzi University of Milano-Bicocca, Italy
William Grizzle University of Alabama at Birmingham, Birmingham, Alabama, USA
Jack K. Horner JKH Consulting, USA
Grant Izmirlian National Cancer Institute, USA
Sarath C. Janga Indiana University - Purdue University, USA
Igor Jurisica University of Toronto, Canada
R. Krishna Murthy Karuturi The Jackson Laboratory, USA
Meik Kunz Universität Erlangen–Nürnberg, Germany
Eva K. Lee Emory University, USA
Lang Li Indiana University - Purdue University, USA
Jack W. London Thomas Jefferson University, USA
Mia Markey University of Texas at Austin, USA
Gary M. Marsh University of Pittsburgh, USA
Geoff McLachlan University of Queensland, Australia
Jill P Mesirov University of California, San Diego, USA
Hiroshi Mizushima National Institute of Public Health, Japan
Michael Ochs Fox Chase Cancer Center, USA
Elissa M. Ozanne University of California, San Francisco, USA
Taesung Park Seoul National University, South Korea
Matea Pavic University Hospital Zurich, Switzerland
Paul Martin Putora Kantonsspital St. Gallen and University of Bern, Switzerland
Kun Qu Stanford University School of Medicine, USA
Joel Saltz Emory University, USA
Ravi Sankar University of South Florida, USA
Roland Schwarz Berlin Institute for Medical Systems Biology, Germany
Simon Sherman University of Nebraska Medical Center, USA
Richard Simon National Cancer Institute, USA
Sudhir Srivastava National Institutes of Health, USA
George S. Stamatakos National Technical University of Athens, Greece
David J. States OncProTech LLC, USA
Mahlet Tadesse Georgetown University, USA
Aik Choon Tan University of Colorado Denver School of Medicine, USA
Alex Tsodikov University of Michigan, USA
William J. Welsh Rutgers University, USA
Ka-Chun Wong City University of Hong Kong, Hong Kong
  • Clarivate Analytics: Emerging Sources Citation Index (ESCI)
  • Directory of Open Access Journals (DOAJ)
  • PubMed Central (PMC)
  • Scopus
  • This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing,
    and Publication of Scholarly Work in Medical Journals
    formulated by the International Committee of
    Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit the journal’s submission site to upload your manuscript.
    Please note that manuscripts not conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of Cancer Informatics will be

    As part of the submission process you will be required to warrant that you are submitting your original
    work, that you have the rights in the work, that you are submitting the work for first publication in the
    Journal and that it is not being considered for publication elsewhere and has not already been published
    elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of
    any copyright works not owned by you.

    Please Read the Manuscript Submission Guidelines below before submitting your manuscript here:

    1. Open Access
    2. Article processing charge (APC)
    3. What do we publish?
      3.1 Aims & scope
      3.2 Article types
      3.3 Writing your paper
      3.3.1 Making your article discoverable 
    4. Editorial policies
      4.1 Peer Review Policy
      4.2 Authorship
      4.3 Acknowledgements
      4.3.1 Writing assistance
      4.4 Funding
      4.5 Declaration of conflicting interests
      4.6 Research ethics and patient consent
      4.7 Clinical Trials
      4.8 Reporting guidelines
    5. Publishing policies
      5.1 Publication ethics
      5.1.1 Plagiarism
      5.1.2 Prior publication
      5.2 Contributor's publishing agreement
    6. Preparing your manuscript
      6.1 Word processing formats
      6.2 Artwork, figures and other graphics
      6.3 Supplemental material
      6.4 Reference style
      6.5 English language editing services
    7. Submitting your manuscript
      7.1 How to submit your manuscript
      7.2 Title, keywords and abstracts
      7.3 Information required for completing your submission
      7.4 ORCID
      7.5 Permissions
    8. On acceptance and publication
      8.1 SAGE Production
      8.2 Continuous publication
      8.3 Promoting your article
    9. Further information

    1. Open Access

    Cancer Informatics is an open access, peer-reviewed journal. Each article accepted by peer review is
    made freely available online immediately upon publication, is published under a Creative Commons
    license and will be hosted online in perpetuity. Publication costs of the journal are covered by the
    collection of article processing charges which are paid by the funder, institution or author of each
    manuscript upon acceptance. There is no charge for submitting a paper to the journal.

    For general information on open access at SAGE please visit the Open Access page or view our Open
    Access FAQs

    Back to top

    2. Article processing charge (APC)

    If, after peer review, your manuscript is accepted for publication, a one-time article processing charge
    (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely
    available online in perpetuity under a Creative Commons license.

    The article processing charge (APC) is $1,848 USD for authors in North America and £1,399 for authors in
    all other countries.*

    *The article processing charge (APC) is payable upon acceptance after peer review and is subject to value
    added tax (VAT) where applicable. If the paying author/institution is based in the European Union, to
    comply with European law, VAT must be added to the APC. Providing a VAT registration number will
    allow an institution to avoid paying this tax, except for UK institutions. Payments can be made in GBP or

    Back to top

    3. What do we publish?

    3.1 Aims & scope

    Before submitting your manuscript to Cancer Informatics, please ensure you have read the Aims
    & Scope.

    3.2 Article types

    Manuscript types eligible for submission are described below.

    1. Case Report

    Case reports present interesting or unusual examples of disease, side effects,
    symptoms, treatments, pathogenesis, or unusual circumstances in medicine and
    healthcare. Articles can be accompanied by pictures if necessary—these require
    informed patient consent to publish—and should contribute to the existing
    literature on the condition they report on. Manuscripts must present out of the
    ordinary cases.

    2. Commentary

    Commentaries are by invitation only. These are short summaries of significant
    recent and forthcoming papers, published elsewhere, that provide additional
    insights, new interpretations or speculation on the relevant topic. These
    manuscripts may include models, which due to space limitations were not
    included or discussed in the original paper.

    Commentaries may be written in free form, meaning that they do not need to be
    structured as a research paper, however it must include an abstract of 150-200
    words. They should be between 1000-2000 words and have no more than 15
    references. Please include keywords for indexing purposes. Figures are
    encouraged, but no more than three. Please give your commentary a brief title
    and add the phrase “Comment on (citation to your original article).” underneath
    the keywords. Commentary material may be peer reviewed at the editor’s

    3. Editorial

    Written by the Editor-in-Chief, deputy Editor-in-Chief, Guest Editor or Associate
    Editor of a journal, editorials are intended to inform readers of changes
    concerning the journal, or to introduce supplements, special issues, or new ideas
    relevant to the journal. In limited circumstances individuals other than the
    individuals listed here may propose an editorial topic if they wish.

    4. Letter to the Editor

    A letter to the Editor is a brief communication that either addresses the contents of
    a published article, or is a correspondence unrelated to a specific article. Its purpose is
    to make corrections, provide alternative viewpoints, or offer counter arguments. Avoid
    logical fallacies and ad hominem attacks. Letters to the Editor must be written in a
    professional tone and include references to support all claims if appropriate.

    A letter to the Editor unrelated to a specific article should not exceed 500 words or have
    more than 3 references. A letter to the Editor pertaining to a recently published article or to
    be published concurrently with an article within the journal should not exceed 800 words or
    have more than 5 references. If an abstract is included, it will automatically be made the first
    paragraph. Letters should not include figures or research material. Letters to the editor are not
    charged an APC.

    5. Meeting Report

    This manuscript type reports on a meeting with specific relevance to the journal
    it is submitted to. Meetings can be international or national conferences or
    institutional seminars.

    6. Methodology

    Methodology manuscripts explain a new methodology or an improvement in
    existing methodologies in therapeutics techniques or medical procedures.

    7. Original Research

    These should detail original experiments/research conducted by the authors.
    Any research on any topic is accepted, provided it falls within the aims and scope
    of the journal. Original research must add to scientific knowledge on the subject
    and must be completed in accordance with ethical principles. Research on
    humans or animals must have applicable ethical approvals.

    8. Review

    A review is a detailed examination including the benefits and drawbacks of a
    medicine, therapeutic technique, computer program, policy, or anything else
    appropriate to the journal. They are substantially composed of a report on
    previous research. Authors wishing to present original ideas in addition should
    choose the Commentary type. All journals accept unsolicited review
    manuscripts for peer review.

    9. Short Commentary

    A short commentary is similar to a commentary but briefer at around 1,000
    words excluding references.

    10. Short Report

    Short reports present new research that adds to previous studies. This can be
    reporting on the reliability or unreliability of research or informing readers of
    new factors that may influence the outcome of the study. Authors must
    acknowledge the work they build upon including any unpublished sources.
    Manuscripts should be no longer than approximately 1,000 words excluding

    11. Short Review

    A short review is similar to a review but briefer at around 1,000 words excluding

    12. Software or Database Review

    Discussing software, code, a database etc. (one of the two prefixes will be
    excluded prior to publication). These articles should review one of these that is
    likely to be useful to a number of researchers in a specific subject area. The
    example data used in software or database reviews should be available to
    readers for non-commercial purposes, and reviewers must be able to use the
    example anonymously. Software or database reviews can be used to directly
    compare the reviewed programs with alternative options.

    13. Technical Advance

    A broad-scoped category of manuscript reporting an advance within the journal's
    scope. New procedures, experiments, standard practices, or computational
    methods should be presented in technical advance articles. They report on
    significant advancements in technology that the reader will benefit from learning

    3.3 Writing your paper

    The SAGE Author Gateway has some general advice and on how to get published, plus links to
    further resources.

    3.3.1 Making your article discoverable 

    When writing up your paper, think about how you can make it discoverable. The title,
    keywords and abstract are key to ensuring readers find your article through search
    engines such as Google. For information and guidance on how best to title your article,
    write your abstract and select your keywords, have a look at this page on the Gateway:
    How to Help Readers Find Your Article Online.

    Back to top

    4. Editorial policies

    4.1 Peer review policy

    The journal’s policy is to have manuscripts reviewed by two expert reviewers. Cancer
    utilizes a single-blind peer review process in which the reviewer’s name and
    information is withheld from the author. All manuscripts are reviewed as rapidly as possible,
    while maintaining rigor. Reviewers make comments to the author and recommendations to the
    Editor-in-Chief who then makes the final decision. 

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for
    possible publication in the journal. In these cases, the peer review process will be managed by
    alternative members of the Board and the submitting Editor / Board member will have no
    involvement in the decision-making process.

    Cancer Informatics is committed to delivering high quality, fast peer-review for your paper, and
    as such has partnered with Publons. Publons is a third party service that seeks to track, verify
    and give credit for peer review. Reviewers for Cancer Informatics can opt in to Publons in order
    to claim their reviews or have them automatically verified and added to their reviewer profile.
    Reviewers claiming credit for their review will be associated with the relevant journal, but the
    article name, reviewer’s decision and the content of their review is not published on the site.
    For more information visit the Publons website

    4.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing
    authors. Those submitting papers should carefully check that all those whose work contributed
    to the paper are acknowledged as contributing authors.
    The list of authors should include all those who can legitimately claim authorship. This is all
    those who:

    (i) Made a substantial contribution to the concept or design of the work; or acquisition,
    analysis or interpretation of data,
    (ii) Drafted the article or revised it critically for important intellectual content,
    (iii) Approved the version to be published,
    (iv) Each author should have participated sufficiently in the work to take public
    responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. Each author should have
    participated sufficiently in the work to take public responsibility for appropriate portions of the

    When a large, multicentre group has conducted the work, the group should identify the
    individuals who accept direct responsibility for the manuscript. These individuals should fully
    meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone
    does not constitute authorship, although all contributors who do not meet the criteria for
    authorship should be listed in the Acknowledgments section. Please refer to the International
    Committee of Medical Journal Editors (ICMJE) authorship guidelines
    for more information on

    4.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an
    Acknowledgements section. Examples of those who might be acknowledged include a person
    who provided purely technical help, or a department chair who provided only general support. 

    4.3.1 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do
    not qualify as authors and so should be included in the Acknowledgements section. Authors
    must disclose any writing assistance – including the individual’s name, company and level of
    input – and identify the entity that paid for this assistance.
    It is not necessary to disclose use of language polishing services.

    Any acknowledgements should appear first at the end of your article prior to your Declaration of
    Conflicting Interests (if applicable), any notes and your References.

    4.4 Funding

    Cancer Informatics requires all authors to acknowledge their funding in a consistent fashion
    under a separate heading. Please visit the Funding Acknowledgements page on the SAGE
    Journal Author Gateway to confirm the format of the acknowledgment text in the event of
    funding, or state that: This research received no specific grant from any funding agency in the
    public, commercial, or not-for-profit sectors.

    4.5 Declaration of conflicting interests

    It is the policy of Cancer Informatics to require a declaration of conflicting interests from all
    authors enabling a statement to be carried within the paginated pages of all published articles.
    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of
    your manuscript, after any acknowledgements and prior to the references. If no conflict exists,
    please state that ‘The Author(s) declare(s) that there is no conflict of interest.

    For guidance on conflict of interest statements, please see the ICMJE recommendations.

    4.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical
    Association Declaration of Helsinki

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct,
    Reporting, Editing, and Publication of Scholarly Work in Medical Journals
    , and all papers
    reporting animal and/or human studies must state in the methods section that the relevant
    Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure
    that you have provided the full name and institution of the review committee, in addition to the
    approval number.

    For research articles, authors are also required to state in the methods section whether
    participants provided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in
    the manuscript text. A statement is required regarding whether written informed consent for 
    patient information and images to be published was provided by the patient(s) or a legally
    authorized representative. Please do not submit the patient’s actual written informed consent with
    your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you
    confirm to us, in writing, that you have obtained written informed consent but the written consent
    itself should be held by the authors/investigators themselves, for example in a patient’s hospital
    record. The confirmatory letter may be uploaded with your submission as a separate file.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

    All research involving animals submitted for publication must be approved by an ethics
    committee with oversight of the facility in which the studies were conducted. The journal has
    adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals
    published by the International Association of Veterinary Editors.

    4.7 Clinical trials

    Cancer Informatics conforms to the ICMJE requirement that clinical trials are registered in a
    WHO-approved public trials registry at or before the time of first patient enrolment as a
    condition of consideration for publication. The trial registry name and URL, and registration
    number must be included at the end of the abstract.

    4.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type
    of study. For example, all randomized controlled trials submitted for publication should include
    a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should
    be uploaded with your submission as a supplementary file. Systematic reviews and metaanalyses
    should include the completed PRISMA flow chart as a cited figure and the completed
    PRISMA checklist should be uploaded with your submission as a supplementary file. The
    EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    Back to top

    5. Publishing policies

    5.1 Publication ethics

    SAGE is committed to upholding the integrity of the academic record. We encourage authors to
    refer to the Committee on Publication Ethics’ International Standards for Authors and view the
    Publication Ethics page on the SAGE Author Gateway.

    5.1.1 Plagiarism

    Cancer Informatics and SAGE take issues of copyright infringement, plagiarism or other breaches
    of best practice in publication very seriously. We seek to protect the rights of our authors and
    we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to
    protect the reputation of the journal against malpractice. Submitted articles may be checked
    with duplication-checking software. Where an article, for example, is found to have plagiarized
    other work or included third-party copyright material without permission or with insufficient
    acknowledgement, or where the authorship of the article is contested, we reserve the right to
    take action including, but not limited to: publishing an erratum or corrigendum (correction); 
    retracting the article; taking up the matter with the head of department or dean of the author's
    institution and/or relevant academic bodies or societies; or taking appropriate legal action.

    5.1.2 Prior publication

    If material has been previously published, it is not generally acceptable for publication in a SAGE
    journal. However, there are certain circumstances where previously published material can be
    considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in
    doubt, contact the Editor at the address given below.

    5.2 Contributor's publishing agreement

    Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s
    Publishing Agreement. Cancer Informatics publishes manuscripts under Creative Commons
    . The standard license for the journal is Creative Commons by Attribution NonCommercial
    (CC BY-NC), which allows others to re-use the work without permission as long as
    the work is properly referenced and the use is non-commercial. For more information, you are
    advised to visit SAGE's OA licenses page.

    Alternative license arrangements are available, for example, to meet particular funder
    mandates, made at the author’s request. 

    Back to top

    6. Preparing your manuscript

    6.1 Word processing formats

    The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and
    (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author

    6.2 Artwork, figures and other graphics

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please
    visit SAGE’s Manuscript Submission Guidelines.

    Figures supplied in color will appear in color online.

    6.3 Supplemental material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images
    etc) alongside the full-text of the article. These will be subjected to peer-review alongside the
    article. For more information please refer to our guidelines on submitting supplemental files,
    which can be found within our Manuscript Submission Guidelines page. 

    6.4 Reference style

    Cancer Informatics adheres to the AMA reference style. Please review the guidelines on AMA to
    ensure your manuscript conforms to this reference style.

    If you use EndNote to manage references, you can download the AMA output file here.

    6.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript
    formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit
    SAGE Language Services on our Journal Author Gateway for further information. 

    Back to top

    7. Submitting your manuscript

    7.1 How to submit your manuscript

    To submit your manuscript to Cancer Informatics, please visit out manuscript submission site.
    Please ensure that references are formatted with AMA reference style

    7.2 Title, keywords and abstracts

    Please supply a title, short title, an abstract and keywords to accompany your article. The title,
    keywords and abstract are key to ensuring readers find your article online through online search
    engines such as Google. Please refer to the information and guidance on how best to title your
    article, write your abstract and select your keywords by visiting the SAGE Journal Author
    Gateway for guidelines on How to Help Readers Find Your Article Online

    7.3 Information required for completing your submission

    You will be asked to provide contact details and academic affiliations for all co-authors via the
    submission system and identify who is to be the corresponding author. These details must match
    what appears on your manuscript. The affiliation listed on the manuscript should be the institution
    where the research was conducted. If an author has moved to a new institution since completing
    the research, the new affiliation can be included in a manuscript note at the end of the paper. At
    this stage please ensure you have included all the required statements and declarations and
    uploaded any additional supplementary files (including reporting guidelines where relevant).

    7.4 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process
    SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID
    provides a persistent digital identifier that distinguishes researchers from every other researcher
    and, through integration in key research workflows such as manuscript and grant submission, 
    supports automated linkages between researchers and their professional activities ensuring that
    their work is recognized.

    We encourage all authors to add their ORCIDs to their SAGE Track accounts and include their
    ORCIDs as part of the submission process. If you don’t already have one you can create one

    7.5 Permissions

    Authors are responsible for obtaining permission from copyright holders for reproducing any
    illustrations, tables, figures or lengthy quotations previously published elsewhere. For further
    information including guidance on fair dealing for criticism and review, please visit our
    Frequently Asked Questions on the SAGE Journal Author Gateway.

    Back to top

    8. On acceptance and publication

    If your paper is accepted for publication after peer review, you will first be asked to complete the
    contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production,
    the corresponding author will be asked to pay the article processing charge (APC) via a payment link.
    Once the APC has been processed, your article will be prepared for publication and can appear online
    within an average of 30 days. Please note that no production work will occur on your paper until the
    APC has been received.

    8.1 SAGE Production

    Your SAGE Production Editor will keep you informed as to your article’s progress throughout the 
    production process. Proofs will made available to the corresponding author via our editing portal 
    SAGE Edit, or by email to the corresponding author and should be returned promptly.  Authors are 
    reminded to check their proofs carefully to confirm that all author information, including names, 
    affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest 
    statements, if any, are accurate. Please note that if there are any changes to the author list at this 
    stage all authors will be required to complete and sign a form authorizing the change.

    8.2 Online publication

    One of the many benefits of publishing your research in an open access journal is the speed to
    publication. With no page count constraints, your article will be published online in a fully
    citable form with a DOI number as soon as it has completed the production process. At this time
    it will be completely free to view and download for all. 

    8.3 Promoting your article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is
    as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help 
    you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.
    In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich,
    share, and measure the impact of their article. Find out how to maximize your article’s impact
    with Kudos

    Back to top

    9. Further information

    Any correspondence, queries or additional requests for information on the Manuscript Submission
    process should be sent to the Cancer Informatics editorial office as follows:

    Barbara Rattner, PhD |

    Back to top